First established by French immunologist Daniel Zagury, M.D, PhD., as a spinoff of Pierre et Marie Curie University. Neovacs became a biotechnology company in 2003 when several investment funds specialized in healthcare industry joined the capital.
Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune diseases.
3-5, Impasse Reille
Tel. : 33 (0)1 53 10 93 00
Fax : 33 (0)1 53 10 93 03
Why should you invest in Neovacs?go to the investors section